Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
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
EPZ33dw9EW63YZ2t
